Triomics Analysis: $15M Raised
What is Triomics?
Triomics leverages generative AI to enhance oncology research and care by accelerating trial enrollment, improving quality, and streamlining healthcare operations.
Employees
50
Founded
2021
Revenue
$9.3-10.5M
Company Stage
Series A
YC Batch
W21
Product Features & Capabilities
- Trial Enrollment, Patient-to-Trial Matching, Clinical Navigators, Quality Improvement, Care Operations, Triaging, Scheduling and Pre-Charting
How much Triomics raised
Series A - $15 million
May 9, 2024Lead Investor: Lightspeed Venture Partners, Nexus Venture Partners, and others.
Who are the founders of Triomics
Investors
- Lightspeed Venture Partners
- General Catalyst
- Nexus Venture Partners
- Y Combinator
Company Pricing
- Pricing is based on a subscription model.
- Detailed pricing plans are not publicly available.
- Custom solutions are offered, with pricing varying based on scale and customization.
- Interested parties should contact Triomics directly for specific pricing information.
